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• Australia is largely self-sufficient in its supply of safe, fresh 
blood products because of the goodwill of non-remunerated, 
volunteer donors, plus rigorous testing and processing 
standards.
• CSL Limited is the sole provider of plasma fractionation 
services in Australia, enjoying exclusive rights under the 
Plasma Fractionation Agreement with the Australian 
Government.
• In the Australia–United States Free Trade Agreement 
(AUSFTA), Australia agreed to review its current contract with 
CSL Limited, and to recommend to the states and territories 
that the process be opened up to overseas tender.
• Overseas tenders for off-shore fractionation services are likely 
to be highly competitive due to their low manufacturing costs 
and accumulated expertise.
• Off-shore fractionation could compromise the safety of 
Australia’s blood supply through delays in processing and 
transportation, issues related to quality control, and even the 
siphoning of stock to overseas markets. This could 
compromise the long-term care of Australian patients and 
create a serious national security risk in the event of a terrorist 
attack or natural disaster.
• Australia’s AUSFTA obligation to recommend changes does 
not equate to an obligation to actually proceed. The states 
and territories should carefully consider whether such 
changes would be in our national interest.
• The long-term security of the Australian people in the current 
security environment is dependent on continuance of an on-
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shore fractionation plant and appropriate back-up facilities.us
of 
ThA tralia, under the National Blood Agreement, has a policy“self-sufficiency” in fresh blood and plasma products.e policy refers to effort rather than outcome, with self-
sufficiency defined as “striving to meet clinical demands using
local product”.1 In recent years, increasing amounts of plasma-
derived and recombinant products have been imported (with
limited policy debate). However, for the most part, plasma prod-
ucts continue to be derived from Australian donations and proc-
essed in Australia (Box 1).2 Whole blood, plasma and platelets
ected by the
IV, hepatitis B
galovirus (to
s Free Trade
letter to this
d and plasma-
derived products to increase considerably above current levels. In
this article, we raise several specific concerns relating to AUSFTA
and the safety, quality, and security of supply of Australia’s blood
and plasma products. We also argue that AUSFTA creates addi-
tional uncertainties by increasing the potential for policy lobbying
based on the threat of so-called “non-violation nullification of
benefits” disputes, although we maintain these must be restricted
to unambiguous textual obligations.5
Australia’s blood and plasma products and AUSFTA
Chapter 15 of AUSFTA (Government Procurement) established an
obligation that government contracts for goods and services must
be equally open to suppliers in both countries.6 A specific annex*,
however, excluded from this obligation “the procurement of
plasma fractionation services” in Australia.7
Nevertheless, in May 2004, the United States Trade Representa-
tive and the Australian Minister for Trade undertook an exchange
of side letters† (a binding part of AUSFTA) on blood products and
plasma fractionation services (Box 2).8 Central to these obligations
is an expiry date for the present contract — the Plasma Fractiona-
tion Agreement with CSL Limited — and the creation of a review
process to consider opening up blood services to competitive
overseas tender. This Review of Australia’s Plasma Fractionation
Arrangements took written submissions in March and April 2006
and is due to report by 1 January 2007.9 Submissions may be
made publicly available once the Review is finalised, but any
submissions containing commercial-in-confidence material, or
where authors indicate that the submission is not to be made
public, will not be published.
The Review is described as “independent”,10 but the Australian
Government is committed under AUSFTA to recommend to the
states and territories that future fractionation arrangements be put
out for tender. The Review’s recommendations may thus shape the
conditions on which the Australian Government makes that
recommendation, or its implementation, should state and territory
agreement be obtained.
The terms of reference of the Review include safety, quality,
security of supply, efficacy and cost. Our concerns relate particu-
larly to the first three of these.
Payment for blood donation and safety concerns
Safety of the Australian blood supply should not be taken for
granted. Blood is a scarce global commodity; paid donors in
developing countries are becoming an increasingly important
source of the world’s plasma.11 In the US, some plasma donors
receive about US$25 per donation or up to US$200 per month,
depending on how often they donate, their blood type and the
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* The annexes of the AUSFTA are attached to the respective Chapters; they are 
part of the text of the Agreement and are legally binding. 
† Side letters are used in the AUSFTA in three main ways: (1) to provide additional 
clarification on how a particular provision of the Agreement will apply; (2) to make 
additional commitments that apply only to one country; (3) to confirm to the other 
country how a nation's current policies or systems operate. 
Only the first two categories constitute an "integral part of the Agreement" and 
are legally binding.r 6 • 18 September 2006
FOR DEBATEspecificity of their serum antibodies.12 Referring others to a
particular collection company earns donors an additional finder’s
fee.13 Reviews have consistently found that paid blood donors are
more at risk of emergent infectious disease and are more likely to
donate in symptomless “window” periods.14,15 In short, blood
sourced from paid donors is less safe than blood from non-
remunerated donors.16 For example, a recent study in São Paulo,
Brazil, found that paid donors were twice as likely as non-
remunerated donors to test positive to Chagas disease.17 The
substantial immigration of people to the US from Central and
South America may therefore have significant consequences for the
safety of the US blood supply, especially given that greater
disadvantage among migrant groups may lead higher-risk people
to donate to supplement their low income. Such factors have led to
major concerns about the safety of blood products in the US,18
where paid donation accounts for about 55% of the blood
supply.19
Paying for blood may not actually increase much needed supply.
A UK study found that while some non-donors rated themselves as
more likely to donate if they were to be paid, a similar number of
existing volunteer donors reported a contrary conclusion.20 Fur-
ther, public health concerns over payment for blood and plasma
must also consider that, by providing payment, those most
vulnerable may be encouraged to donate too frequently, causing
undue and potentially long-term harm to their own health.
Australia’s blood safety precautions
The current battery of safety tests performed on blood collected in
Australia is neither perfect in coverage nor in accuracy. Donors are
therefore restricted to people who are healthy and considered to be
at low risk of blood-transmissible disease.3 For example, the
Australian Red Cross Blood Service does not accept donations
from people who have been in prison within the previous 12
months, or those who have had a recent tattoo or piercing.
Obviously, blood cannot be screened for as yet unidentified or
newly emergent diseases, as transmission of HIV and hepatitis C to
blood product recipients in the 1980s in Australia (and elsewhere)
attests. There is still no test to detect variant Creutzfeldt–Jakob
disease.3 Australian national self-sufficiency in blood and plasma is
therefore desirable given the greater risks resulting from paid
donations in other countries.
For plasma, the Therapeutic Goods Administration tracks each
item donated and approves the circumstances of collection and
processing of imported products.
Plasma fractionation arrangements in Australia
CSL Limited is currently the sole provider of plasma fractionation
services in Australia, enjoying exclusive rights under the Plasma
Fractionation Agreement with the Australian Government. Until
2005, CSL provided most of the clotting agents used in haemo-
philia care. However, since the government’s decision to fund
recombinant therapy, about 85% of haemophiliacs use imported
clotting agents21 purchased from four other pharmaceutical com-
panies (Box 1), which share in annual business worth $90
million.2 The Plasma Fractionation Agreement between the Com-
monwealth Government and CSL is due to end in December 2009,
but the AUSFTA exchange of side letters indicates it can be
terminated earlier.22
Implications of overseas tendering for plasma 
fractionation
If a large overseas company were to use its legal expertise and
economies of scale to gain this further business, one probable
scenario would be that plasma donated in Australia could be
shipped overseas for fractionation and then returned. In such
circumstances, there is a possibility that essential safety measures
— though specified in written guidelines — might not be as
rigorously monitored as they are in Australia. As CSL is already one
of the world’s largest fractionators and obtains source product free
of charge, any greater “efficiency” from competitive tendering may
be the result of cost-cutting on safety infrastructure or procedures.
A second scenario is that a successful overseas tenderer could
take over the CSL plant, but the resultant reorganisation could
incrementally introduce standards and practices less effective than
those presently in place. For example, cost-cutting may promote
an increase in batch size, escalating both the chance of contamina-
tion and the number of people potentially affected. Recall capacity
and timely donor tracing may be diminished.
Changing Australia’s plasma fractionation arrangements would
also affect products in other countries. CSL is the national provider
of fractionation services to New Zealand, Malaysia, Hong Kong
and Singapore.2 Further, Australia’s recent agreement with New
Zealand to establish a Trans-Tasman joint regulatory agency on
therapeutic goods may mean that New Zealand will be required to
open its own processing arrangements to tender, or could be
forced to “piggyback” with new Australian arrangements.
Finally, shipping plasma offshore for processing would reduce
Australia’s capacity to rapidly respond to a major emergency such
as a natural disaster or terrorist attack (where large quantities of
plasma are required urgently), or to contaminated supply, particu-
larly if international transportation is hampered.
AUSFTA and further concerns about a safe blood supply
Of further concern is that a proportion of Australia’s cheap and
comparatively safe blood supply could be siphoned off into
1 Sources of blood and plasma products2
Australian Red Cross Blood Service
Fresh blood products — whole blood, red blood cells, platelets, 
frozen plasma, cryoprecipitate, buffy coat (white cells), plasma for 
fractionation
CSL Limited
Albumin, immunoglobulin (Rh(D), IVIg [intravenous infusion of 
immunoglobulins] and hyperimmune products), plasma-derived 
clotting factors, blood grouping sera, reagent red cell products, 
Factors XI and XIII
Baxter Healthcare Pty Ltd
Recombinant Factor VIII, Protein C, Factor VII concentrate, Factor 
Eight Inhibitor Bypass Agent (FEIBA)
Wyeth Australia Pty Ltd
Recombinant Factor IX
Novo Nordisk Pharmaceuticals Pty Ltd
Recombinant Factor VIIa
Octapharma (Australia) Pty Ltd
Immunoglobulin IVIg ◆MJA • Volume 185 Number 6 • 18 September 2006 321
FOR DEBATEoverseas markets, where it would be highly valued as a low-risk
product, being sourced from non-remunerated donors.
There is also little in AUSFTA to prevent future tendering for the
collection of blood and plasma by for-profit companies as well,
potentially igniting competition for donors, loss of reliance on
volunteer donations, and reduced safety of the blood supply. It is
foreseeable that non-remunerated donations to the Australian Red
Cross Blood Service could diminish in such an environment,
driving up the costs of sourcing plasma and cellular products
through the provision of payment to donors. It would cost more to
obtain the same — or lesser — amount of product.
AUSFTA also opens the door to the importation of more blood
products from the US and elsewhere, from paid sources within the
US and from the poor in developing countries, as Australia no longer
requires that a US product demonstrates significant clinical advan-
tage over an Australian produced product (Box 2, Paragraph 6).
Scope for potential breaches of AUSFTA
An additional concern from the AUSFTA side letter on blood
products is Australia’s commitment to recommend that competi-
tive tenders be linked to a non-violation nullification of benefits
(NVNB) article in Chapter 21.2(c) (Box 2). An NVNB claim can be
made in cases where it is argued that the “spirit” of a thoroughly
unambiguous (clearly agreed) treaty provision has been breached,
even in the absence of any technical (actual) contravention. The
World Trade Organization (WTO) has held that such claims
require detailed justification and, despite US objections, has
recently continued a moratorium on their use under the Trade-
Related aspects of Intellectual Property Rights (“TRIPS”) Agree-
ment.23 In one dispute case, European Communities — Measures
Affecting Asbestos and Asbestos-Containing Products, the Appellate
Body agreed with a previous panel24 that NVNB claims “should be
approached with caution and should remain an exceptional
remedy”.25 It explicitly left open the question of whether a party
could have “reasonable expectations” for NVNB purposes in
relation to “continued market access for products which are shown
to pose a serious risk to human life or health”.25 It is uncertain how
NVNB claims interact with Article 26 of the Vienna Convention on
the Law of Treaties, incorporating the principle of pacta sunt
servanda: “Every treaty in force is binding upon the parties to it and
must be performed by them in good faith”.26 NVNB claims appear
to undermine this fundamental principle of international law by
subsequent reinterpretations based on the “spirit” of the agree-
ment. In this case, the Australian Government has only agreed to
recommend overseas tendering for plasma fractionation. If that
recommendation is made, but the states and territories decide to
deny overseas tenders, the US may lobby for, but cannot legally
enforce, an ambit NVNB claim against Australia. Would such
lobbying efforts undermine the rule of law in international rela-
tions by seeking to enforce the “spirit” of a non-existent or
deliberately vague obligation to actually open up plasma fractiona-
tion to competitive tender?
Securing Australia’s plasma fractionation supplies
The current system of a single fractionation plant could be made
more robust. At present, there may be delays caused by equipment
breakdown, or the Australian plant could become a future terrorist
target. Rather than primarily sourcing plasma fractionation services
from overseas (the Australian Government’s preferred option), the
present system could be improved if instead an arrangement is
made for a suitable and ready alternative source to be accessed
only in the event of significant delays in local manufacture.
Currently, CSL’s overseas plants provide back-up, but the establish-
ment of an additional, pre-approved offshore alternative source —
for emergency use only in case of an ongoing supply problem —
could lessen the impact (and perhaps the likelihood) of a terrorist
attack at the CSL plant. Further, the presence of a viable alternative
source may have the additional benefit of acting as a catalyst for
greater efficiencies (in production rather than cost) at CSL,
reducing the likelihood of manufacturing delays.
Future impact
The outcome of the Review of Australia’s Plasma Fractionation
Arrangements, as required by AUSFTA, could have major endur-
ing consequences for the Australian health care system, its self-
sufficiency in blood supply from low-risk donations, and its
capacity to respond to natural and other disasters. Australia’s
2 Australia–United States Free Trade Agreement 
exchange of side letters on blood plasma and blood 
fractionation services8
1. Any contract with a central government entity of Australia for 
blood fractionation services in effect on the date of entry into force 
of the Agreement shall conclude no later than 31 December 2009, or 
earlier if Australia deems it appropriate.
2. Australia shall undertake a review of its arrangements for the 
supply of blood fractionation services that shall conclude no later 
than 1 January 2007. The Commonwealth Government will 
recommend to Australia’s States and Territories that future 
arrangements for the supply of such services be done through 
tender processes consistent with Chapter 15 (Government 
Procurement) of the Agreement.
3. Should the Commonwealth and State and Territory governments 
reach agreement [to move] to tender processes consistent with 
Chapter 15, Australia shall withdraw its Annex 15-A, Section 5 
reservation regarding the procurement of such services.
4. A Party may require any producer of blood plasma products or 
supplier of blood fractionation services to fulfil requirements 
necessary for ensuring the safety, quality, and efficacy of such 
products. Such requirements shall not be prepared, adopted, or 
applied with a view to, or with the effect of, creating unnecessary 
obstacles to trade.
5. A Party may require that blood plasma products for use in its 
territory be derived from blood plasma collected in the territory of 
that Party.
6. Australia confirms that it will not apply any requirement for an 
applicant for approval of the marketing and distribution of a U.S. 
blood plasma product to demonstrate significant clinical advantage 
over Australian-produced products.
7. Article 21.2(c)* (Scope of Application) of the Agreement shall 
apply to paragraphs 1 through 6.
. . . this letter and your letter in reply . . .  shall constitute an integral 
part of the Agreement.
* Article 21.2(c): a benefit the Party could reasonably have expected to accrue 
to it under Chapters Two (National Treatment and Market Access for Goods), 
Three (Agriculture), Five (Rules of Origin), Ten (Cross-Border Trade in Ser-
vices), Fifteen (Government Procurement), or Seventeen (Intellectual Property 
Rights) is being nullified or impaired as a result of a measure that is not 
inconsistent with this Agreement.5 ◆322 MJA • Volume 185 Number 6 • 18 September 2006
FOR DEBATEcapacity for future self-sufficiency in fractionation would also be
lost, while diminishing CSL’s core business could prove a major
setback to Australia’s emerging biotechnology industry. The Aus-
tralian public is entitled to ask why both major political parties
agreed to include Australia’s plasma fractionation in the trade deal
with the US, given its public health significance. It is possible that
industry lobbying may take advantage of the fact that dispute
settlement is likely to favour trade facilitation over the protection
of public health.27 If the Review finds in favour of opening up
Australia’s fractionation arrangements to overseas tender, the states
and territories should carefully consider whether such changes
would be in Australia’s national interest.
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